Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective

被引：19

作者：

Pizevska, Maja ^{[1
]}

Kaeda, Jaspal ^{[2
]}

Fritsche, Enrico ^{[2
]}

Elazaly, Hisham ^{[1
]}

Reinke, Petra ^{[1
,2
]}

Amini, Leila ^{[1
,2
]}

机构：

[1] Charite Univ Med Berlin, Berlin Inst Hlth, Ctr Regenerat Therapies, Berlin, Germany

[2] Charite Univ Med Berlin, Berlin Ctr Adv Therapies BeCAT, Berlin, Germany

来源：

FRONTIERS IN MEDICINE | 2022年 / 9卷

基金：

欧盟地平线“2020”;

关键词：

regulatory affairs; European Medicines Agency; legislation; regulatory science; Paul-Ehrlich-Institute (PEI); advanced therapy medicinal product (ATMP); cell and gene therapies; REGULATORY PATHWAYS; GENE THERAPIES; CELL; CHALLENGES; INNOVATION; SCIENCE;

D O I：

10.3389/fmed.2022.757647

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Advanced Therapy Medicinal Products (ATMPs) comprising cell, gene, and tissue-engineered therapies have demonstrated enormous therapeutic benefits. However, their development is complex to be managed efficiently within currently existing regulatory frameworks. Legislation and regulation requirements for ATMPs must strike a balance between the patient safety while promoting innovations to optimize exploitation of these novel therapeutics. This paradox highlights the importance of on-going dynamic dialogue between all stakeholders and regulatory science to facilitate the development of pragmatic ATMP regulatory guidelines.

引用

页数：8

共 50 条

[41] CURRENT DEVELOPMENTS IN THE REGULATION OF ADVANCED THERAPY MEDICINAL PRODUCTS
Ruiz, S.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 15 - 16
[42] Advanced therapy medicinal products in China: Regulation and development
Lu, Jiaqi
Xu, Longchang
Wei, Wei
He, Wu
MEDCOMM, 2023, 4 (03):
[43] Participation of patients in the development of advanced therapy medicinal products
Bignami, F.
Kent, A. J.
di Paola, M. Lipucci
Meade, N.
BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2011, 54 (07) : 839 - 842
[44] REIMBURSEMENT PATHWAY FOR ADVANCED THERAPY MEDICINAL PRODUCTS IN BULGARIA
Djambazov, S.
Vutova, Y.
Dacheva, A.
Koleva-Kolarova, R.
Encheva-Malinova, M.
VALUE IN HEALTH, 2022, 25 (07) : S472 - S472
[45] Is the Conjunctiva a Potential Target for Advanced Therapy Medicinal Products?
Diebold, Yolanda
Garcia-Posadas, Laura
PHARMACEUTICS, 2021, 13 (08)
[46] Advanced therapy medicinal products, the promise of significant progress
Guerriaud, Mathieu
ACTUALITES PHARMACEUTIQUES, 2019, 58 (583): : 1 - 1
[47] SAFETY VIGILANCE OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS)
Jimenez-Martin, C. M.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 17 - 18
[48] Risk management considerations and advanced therapy medicinal products
Ruppert-Seipp, G.
Muller, S.
Berg, P.
Funk, M. B.
HUMAN GENE THERAPY, 2022, 33 (23-24) : A194 - A194
[49] European regulatory experience with advanced therapy medicinal products
Lisbeth Barkholt
Caroline Voltz-Girolt
June Raine
Tomas Salmonson
Martina Schüssler-Lenz
Nature Reviews Drug Discovery, 2019, 18 : 8 - 9
[50] Advanced Therapy Medicinal Products: What's in a Name?
Jiskoot, Wim
JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (11) : 3282 - 3284

← 1 2 3 4 5 →